Teva settles patent dispute with Aurobindo

Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Chugai settles cancer drug patent dispute with US firm

10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Europe

Teva breached antitrust rules over Copaxone, says EU

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

More on this story

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Chugai settles cancer drug patent dispute with US firm

10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Europe

Teva breached antitrust rules over Copaxone, says EU

More on this story

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Chugai settles cancer drug patent dispute with US firm

10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Europe

Teva breached antitrust rules over Copaxone, says EU